ADMA Biologics

ADMAPhase 3

ADMA Biologics is an end-to-end commercial biopharmaceutical company leading a new age of plasma-derived specialty biologics, with a focus on improving the lives of immune compromised patients and those at risk for certain infections. The company has built a vertically integrated model encompassing plasma collection, proprietary manufacturing, and commercialization of FDA-approved immune globulin products. ADMA's strategic direction emphasizes achieving plasma self-sufficiency, expanding its product portfolio, and leveraging its patented immunotechnology platform for future growth.

Market Cap

$3.4B

Focus

Biologics

ADMA · Stock Price

USD 14.32+12.69 (+778.53%)

Historical price data

AI Company Overview

Technology Platform

Patented immunotechnology platform featuring a proprietary microneutralization assay for quantitatively measuring neutralizing antibody titers in plasma, enabling the production of targeted plasma-derived biologics.

Pipeline Snapshot

7 drugs in pipeline, 2 in Phase 3

Drug	Indication	Stage
Asceniv™	Primary Immune Deficiency	Approved
Bivigam	Humoral Immune Response	Approved
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]	Primary Immune Deficiency Disorders (PIDD)	Phase 3
RI-002	Primary Immune Deficiency Disorder	Phase 3
Hepatitis C Immune Globulin Intravenous (Human) 5%	Sequelae of Viral Hepatitis	Phase 2

Funding History

Total raised: $105M

PIPE$75MPerceptive AdvisorsMar 15, 2021

IPO$30MUndisclosedOct 10, 2013

Opportunities

Key growth opportunities include achieving plasma supply self-sufficiency to reduce costs and secure supply, expanding market share for ASCENIV and BIVIGAM in the growing IVIG market, and leveraging the contract manufacturing capabilities for additional revenue.

The vertically integrated model provides a platform for potential future pipeline expansion.

Risk Factors

Major risks include intense competition from large plasma therapy companies, regulatory hurdles in plasma collection and manufacturing, dependence on a small product portfolio, and the capital-intensive nature of the business requiring continued investment and a clear path to profitability.

Competitive Landscape

ADMA competes with large global players like Takeda, Grifols, and CSL Behring in the plasma-derived therapeutics market. Its primary differentiation is its vertically integrated, U.S.-based model controlling plasma collection, proprietary manufacturing with patented immunotechnology, and a focused commercial strategy on specialty immune globulin products.

Publications

Patents

Pipeline